April 2018 in “Journal of Investigative Dermatology” This study identified the osteopontin-derived peptide, FOL-005, as a potential inhibitor of unwanted human hair growth by promoting catagen development without reducing stem cell numbers or showing toxicity.
19 citations
,
September 2019 in “British Journal of Dermatology” This study found that a novel peptide, FOL-005, derived from osteopontin, significantly inhibited hair growth in human hair follicles both ex vivo and in vivo, suggesting potential as a treatment for unwanted hair growth.
17 citations
,
December 2001 in “Journal of Investigative Dermatology” This study found that osteopontin mRNA is abundantly expressed in dermal papilla cells during the catagen phase of hair growth in rats, suggesting a role in this phase.
1 citations
,
June 2000 in “PubMed” This study observed that osteopontin mRNA levels in rat hair follicles vary throughout the hair cycle, peaking during the catagen phase and disappearing in the telogen and anagen phases.
27 citations
,
June 2023 in “Nature” In this study using genetic mouse models, researchers discovered that senescent melanocytes in nevi secrete osteopontin, which activates hair stem cells, enhancing hair growth; this process is mirrored in human hairy nevi, suggesting a potential therapeutic target for regenerative disorders.